8-K: 60 Degrees Pharma to Launch Pivotal Babesiosis Study for Tafenoquine Following FDA Meeting

60 Degrees Pharmaceuticals plans to initiate a pivotal clinical study for tafenoquine to treat hospitalized babesiosis patients after a positive Type C meeting with the FDA.

Summary

• 60 Degrees Pharmaceuticals (60P) is moving forward with a pivotal clinical study of tafenoquine for hospitalized babesiosis patients.
• This decision follows a Type C meeting with the FDA on January 17, 2024, where the FDA indicated the proposed study could be sufficient for regulatory approval if a clinical endpoint is used.
• The company is revising the study protocol based on the FDA's feedback and aims to begin patient enrollment in the summer of 2024.
• The study will be a double-blind, placebo-controlled trial at three hospitals in the northeastern United States.
• Babesiosis is a tick-borne illness with an estimated 47,000 cases per year in the U.S., often co-occurring with Lyme disease.
• Tafenoquine is currently approved for malaria prophylaxis under the name ARAKODA but not for babesiosis treatment.

Sentiment

Score: 7

Explanation: The document is positive due to the progress in clinical trials and alignment with the FDA, but there are risks and uncertainties associated with the development process and the company's financial situation.

Positives

• The FDA has indicated that the proposed study design could be sufficient for regulatory approval.
• The company has a clear path forward for the clinical study after the Type C meeting with the FDA.
• Tafenoquine is already approved for malaria, which may streamline the approval process for babesiosis.
• The study addresses an unmet medical need for a new treatment for hospitalized babesiosis patients.
• The company has received funding from the United States Army Medical & Materiel Development Activity.

Negatives

• Tafenoquine is not currently approved for the treatment of babesiosis.
• The company must revise the study protocol based on FDA feedback.
• There is no guarantee that the company will receive Institutional Review Board or FDA approval when the protocol is resubmitted.
• The company has no manufacturing capacity which puts them at risk of delays.
• The company has a history of losses and may not be able to continue as a going concern.

Risks

• The company may not be able to successfully conduct planned clinical trials.
• There is a risk that the FDA may require changes to the study protocol at any time.
• The company has no manufacturing capacity which puts them at risk of lengthy and costly delays of bringing their products to market.
• The company may not be able to obtain FDA approval for the babesiosis indication.
• The company may not be eligible for Australian government research and development tax rebates.
• There is substantial doubt as to the company's ability to continue as a going concern.

Future Outlook

The company plans to initiate patient enrollment for the pivotal babesiosis study in the summer of 2024, pending finalization of the study protocol and regulatory approvals. The company is also working to expand the indications for tafenoquine beyond malaria prevention.

Management Comments

• Geoff Dow, Chief Executive Officer of 60 Degrees Pharmaceuticals, stated that the Type C meeting with the FDA led to mutual alignment on the development plan for tafenoquine in treating hospitalized babesiosis patients.
• He also expressed excitement to advance the study, highlighting the increasing prevalence of tick-borne illnesses like babesiosis.

Industry Context

This announcement is significant as it addresses the growing concern of tick-borne illnesses, particularly babesiosis, which is becoming more prevalent in the U.S. The development of a new treatment option could fill a critical gap in the market, as current treatments may not be fully effective or have significant side effects.

Comparison to Industry Standards

• The development of tafenoquine for babesiosis is a novel approach, as the drug is currently approved for malaria prophylaxis.
• Other companies are also working on treatments for babesiosis, but there are no direct comparables for a repurposed malaria drug.
• The company's approach is unique in that it is leveraging an existing approved drug for a new indication, which could potentially expedite the approval process.
• The company is working with the FDA to ensure the study design meets regulatory requirements, which is a standard practice in the pharmaceutical industry.

Stakeholder Impact

• Shareholders may see potential value in the company's progress in developing a new treatment for babesiosis.
• Healthcare providers may have a new treatment option for hospitalized babesiosis patients.
• Patients with babesiosis may benefit from a new treatment option.
• Employees may be impacted by the company's progress and future growth.

Next Steps

• The company will revise the study protocol based on FDA feedback.
• The company will resubmit the protocol under its malaria Investigational New Drug Application.
• The company will seek Institutional Review Board approval for the study.
• The company plans to initiate patient enrollment in the summer of 2024.

Key Dates

Keywords

tafenoquine, babesiosis, clinical study, FDA, ARAKODA, infectious diseases, pivotal trial, regulatory approval, tick-borne illness